Obermatt
See Similar Stocks →

BioVersys

SWX:BIOV · CH0210362643
PharmaceuticalsX-Small

360

11
Profit price73
Owner Earnings Yield1
Dividend Yield1
Price/Sales8
EV / Gross Profit13
Price/Book19
Return on Capital25
Cash Return on Capital18
Return on Equity12
Profit margins15
Accruals68
Owner Earnings Margin4
Sales growth58
Profit growth14
Reinvestment1
Price momentum24
Debt load40
Refinancing29
Debt Payback1
Liquidity20
Analyst ratings100
Opinion Changes50
Price Target Upside72
Market mood71
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

BioVersys doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountrySwitzerland
IndustryPharmaceuticals
SizeX-Small
TypePublic Company
ExchangeSWX
Founded2010
Employees36
Websitebioversys.com
ISINCH0210362643
Last UpdateApr 2, 2026
Indices
SPI (Switzerland)
Themes
PulmonologyRespiratoryInfectious DiseasesBiotechnologyPharmaceutical

Description

Analysis

Weak and unloved

BioVersys AG is weak and unloved: below-average business metrics and a price that reflects that disappointment.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 4/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
1
2026

All-time high

6

Mar 2026

All-time low

1

Jun 2026

Average rank

4

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
8
—
—
—
Price/Earnings
78
—
—
—
Price/Book
19
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
23
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare BioVersys with its peers
Newron Pharmaceuticals
SWX:NWRN
15
CountryItaly
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
GSK
LSE:GSK
72
CountryUK
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
GH Research
NMQ:GHRS
57
CountryIreland
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
ABIVAX
PAR:ABVX
26
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Jazz Pharmaceuticals
NSQ:JAZZ
91
CountryIreland
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Curatis Holding
SWX:CURN
70
CountrySwitzerland
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →